Usability of German hospital administrative claims data for healthcare research: General assessment and use case of multiple myeloma in Munich university hospital in 2015-2017

PLoS One. 2022 Jul 28;17(7):e0271754. doi: 10.1371/journal.pone.0271754. eCollection 2022.

Abstract

Objectives: To assess the usability of German hospital administrative claims data (GHACD) to determine inpatient management patterns, healthcare resource utilization, and quality-of-care in patients with multiple myeloma (PwMM).

Methods: Based on German tertiary hospital's claims data (2015-2017), PwMM aged >18 years were included if they had an International Classification of Diseases, Tenth Revision, code of C90.0 or received anti-MM therapy. Subgroup analysis was performed on stem cell transplantation (SCT) patients.

Results: Of 230 PwMM, 59.1% were men; 56.1% were aged ≥65 years. Hypertension and infections were present in 50% and 67.0%, respectively. Seventy percent of PwMM received combination therapy. Innovative drugs such as bortezomib and lenalidomide were given to 36.1% and 10.9% of the patients, respectively. Mean number of admissions and mean hospitalization length/patient were 3.69 (standard deviation (SD) 2.71 (1-16)) and 12.52 (SD 9.55 (1-68.5)) days, respectively. In-hospital mortality was recorded in 12.2%. Seventy-two percent of SCT patients (n = 88) were aged ≤65 years, 22.7% required second transplantation, and 89.8% received platelet transfusion at a mean of 1.42(SD 0.63 (1-3)).

Conclusion: GHACD provided relevant information essential for healthcare studies about PwMM from routine care settings. Data fundamental for quality-of-care assessment were also captured.

MeSH terms

  • Aged
  • Bortezomib / therapeutic use
  • Female
  • Health Services Research
  • Hospitals
  • Humans
  • Lenalidomide / therapeutic use
  • Male
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / therapy
  • Retrospective Studies

Substances

  • Bortezomib
  • Lenalidomide

Grants and funding

The author(s) received no specific funding for this work.